½ÃÀ庸°í¼­
»óǰÄÚµå
1799505

¼¼°èÀÇ ÁÖÀÔ ÆßÇÁ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ½ÃÀå ±Ô¸ð ºÐ¼® - À¯Çüº°, ÀûÀÀÁõº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° ¿¹Ãø(2025-2035³â)

Global Infusion Pump Software Market Size, Share & Trends Analysis Report, By Type, By Indication, By End User, and Regional Forecasts 2025-2035

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® 285 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ÁÖÀÔ ÆßÇÁ ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº 2024³â¿¡ ¾à 10¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2025-2035³â ¿¹Ãø ±â°£ µ¿¾È CAGR 2.21%·Î ²ÙÁØÈ÷ È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù. ÁÖÀÔ ÆßÇÁ ¼ÒÇÁÆ®¿þ¾î´Â ÃֽŠÁÖÀÔ ¿ä¹ýÀÇ ¹éº»À» Çü¼ºÇÏ°í ¾à¹°°ú ÁÖÀÔÀÇ Åõ¿©¿¡ Á¤È®¼º, ¾ÈÀü¼º ¹× »óÈ£ ¿î¿ë¼ºÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ Á¤±³ÇÑ ¼ÒÇÁÆ®¿þ¾î´Â º¹¿ë·®ÀÇ Á¤È®¼ºÀ» °ü¸®Çϰí, º´¿ø Á¤º¸ ½Ã½ºÅÛ°ú ÅëÇÕÇϸç, ÀÓ»ó ÇÁ·ÎÅäÄÝÀÇ Áؼö¸¦ º¸ÀåÇÔÀ¸·Î½á ȯÀÚÀÇ ¾ÈÀü°ú ¾÷¹« È¿À²¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ´Â °ÍÀº ½º¸¶Æ® ÁÖÀÔ ½Ã½ºÅÛÀÇ Ã¤¿ëÀÌ Áõ°¡Çϰí ÀÖ´Â °Í, Àå±â ÁÖÀÔ ¿ä¹ýÀ» ÇÊ¿ä·Î ÇÏ´Â ¸¸¼º ÁúȯÀÇ ¸¸¿¬ÀÌ È®´ëµÇ°í ÀÖ´Â °Í, Åõ¾à ¹Ì½º¸¦ ÃÖ¼ÒÈ­Çϱâ À§ÇÑ ÀÇ·á ÀÚµ¿È­¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ´Â °ÍÀÔ´Ï´Ù. µ¥ÀÌÅÍ ÁÖµµÇü ÀÇ·á°¡ ±Þ¼ÓÈ÷ Ç¥ÁØÈ­µÇ°í ÀÖ´Â ÇöÀç, ÁÖÀÔ ÆßÇÁ ¼ÒÇÁÆ®¿þ¾î´Â ½Ç½Ã°£ ¸ð´ÏÅ͸µ°ú ÀÓ»ó ÀÇ»ç °áÁ¤ Áö¿øÀÇ Áß¿äÇÑ ½ÇÇö ¼ö´ÜÀ¸·Î¼­ ±â´ÉÇϰí ÀÖ½À´Ï´Ù.

ÀÇ·á¿¡¼­ DX(µðÁöÅÐ º¯È¯) °¡¼ÓÈ­´Â ¿öÅ©Ç÷οì È¿À²¼º ÃÖÀûÈ­, ¾à¹° À¯ÇØ »ç·Ê °¨¼Ò, ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØ Áؼö¸¦ ¿ä±¸ÇÏ´Â ÀÇ·á Á¦°ø¾÷üÀÇ ÁÖÀÔ ÆßÇÁ ¼ÒÇÁÆ®¿þ¾î¿¡ ´ëÇÑ ¼ö¿ä¸¦ Å©°Ô È®´ëÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ¾à¹° °ú¿À°¨¼Ò ½Ã½ºÅÛ(DERS)ÀÇ ÅëÇÕ°ú ÀüÀÚ ÀÇ·á ±â·Ï(EHR)°úÀÇ ¿øÈ°ÇÑ »óÈ£ ¿î¿ë¼º°ú °°Àº ±â¼úÀû Áøº¸µµ ¼ö¿ä¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¾÷°èÀÇ º¸°í¿¡ µû¸£¸é, Åõ¾à ½Ç¼ö´Â ¸Å³â ¼öõ ¸íÀÇ ¿¹¹æ °¡´ÉÇÑ »ç¸ÁÀÇ ¿øÀÎÀÌ µÇ°í ÀÖÀ¸¸ç, ÀÇ·á ½Ã¼³Àº ¸®½ºÅ©¸¦ ¼±Á¦ÀûÀ¸·Î ½Äº°ÇÏ°í °æ°¨ÇÒ ¼ö ÀÖ´Â °ß°íÇϰí Áö´ÉÀûÀÎ ¼ÒÇÁÆ®¿þ¾î Ç÷§Æû¿¡ ÅõÀÚ¸¦ Ã˱¸Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ´ç´¢º´, ¾Ï, ¼ö¼ú ÈÄÀÇ Äɾ ´ëÇÑ ¿ä±¸ÀÇ °íÁ¶°¡ º¸±Þ¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ¾î, AI¸¦ Ȱ¿ëÇÑ ÁÖÀÔ ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ °³¹ßÀÌ Çõ½ÅÀÇ »õ·Î¿î ±âȸ¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº µµÀÔ ºñ¿ë, ·¹°Å½Ã ½Ã½ºÅÛ °£ÀÇ »óÈ£ ¿î¿ë¼º Á¦ÇÑ, »çÀ̹ö º¸¾È ¹®Á¦ µîÀÇ °úÁ¦´Â ¿¹Ãø ±â°£ µ¿¾È ÀáÀçÀûÀÎ ¾ïÁ¦¿äÀÎÀ¸·Î ³²¾Æ ÀÖ½À´Ï´Ù.

Áö¿ªº°·Î, ºÏ¹Ì´Â ÇöÀç ÁÖÀÔ ÆßÇÁ ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, Áøº¸µÈ ÀÇ·á ÀÎÇÁ¶ó, °­·ÂÇÑ ±ÔÁ¦ Áؼö Ʋ, ÀÇ·á ¼ÒÇÁÆ®¿þ¾î Çõ½ÅÀÇ Á¶±â µµÀÔ¿¡ Áö¿øµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ¹Ì±¹Àº ½º¸¶Æ® ÁÖÀÔ ½Ã½ºÅÛÀÇ º¸±Þ·üÀÌ ³ô°í ÀÇ·á ³×Æ®¿öÅ© Àüü¿¡¼­ EHRÀÌ ÅëÇÕµÇ¾î ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. À¯·´Àº ÀÇ·á µðÁöÅÐÈ­ÀÇ ÁøÀü, ȯÀÚ ¾ÈÀü¿¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿øÀûÀÎ ´ëó, µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º µîÀÇ ³ª¶ó¿¡¼­ È®¸³µÈ ÀÓ»ó ±âÁØ µî¿¡ °ßÀÎµÇ¾î ±Ù¼ÒÇÑ Â÷ÀÌ·Î °è¼ÓµÇ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·áºñ Áõ°¡, Áß±¹, Àεµ µî ½ÅÈï±¹ÀÇ º´¿øÀÇ ±Þ¼ÓÇÑ Çö´ëÈ­, ¸¸¼º Áúȯ °ü¸® ÇÁ·Î±×·¥ÀÇ ±ÞÁõ¿¡ ÈûÀÔ¾î 2025-2035³â °¡Àå ±Þ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ÇÑÆí Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿Í ¶óƾ¾Æ¸Þ¸®Ä«¿¡¼­´Â ÁøÇà ÁßÀÎ ÀÇ·á °³Çõ°ú ÀÇ·á IT ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ°¡ ¹ÚÂ÷¸¦ °¡ÇØ ÁÖÀÔ ÆßÇÁ ¼ÒÇÁÆ®¿þ¾îÀÇ µµÀÔÀÌ Á¡Â÷ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ¸ñÀûÀº ÃÖ±Ù ¿©·¯ ºÎ¹® ¹× ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ¹àÈ÷°í ÇâÈÄ ¸î ³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â ºÐ¼® ´ë»ó ±¹°¡¿¡¼­ ¾÷°èÀÇ ÁúÀû ¹× ¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ½ÃÀå Àü¸Á ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃßÁø ¿äÀΰú µµÀü°ú °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ¿Í Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¸¶ÀÌÅ©·Î ½ÃÀåÀÇ ÀáÀçÀûÀÎ ±âȸµµ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ »ó¼¼ÇÑ ºÎ¹® ¹× ÇÏÀ§ ºÎ¹®Àº ´ÙÀ½°ú °°½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼¼°èÀÇ ÁÖÀÔ ÆßÇÁ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ºÐ¼® ¹üÀ§ ¹× ¼ö¹ý

  • ºÐ¼® ¸ñÀû
  • ºÐ¼® ¹æ¹ý
    • ¿¹Ãø ¸ðµ¨
    • Ã¥»ó ºÐ¼®
    • ÇÏÇâ½Ä ¹× »óÇâ½Ä Á¢±Ù
  • ºÐ¼® ¼Ó¼º
  • ºÐ¼® ¹üÀ§
    • ½ÃÀå Á¤ÀÇ
    • ½ÃÀå ±¸ºÐ
  • ºÐ¼® ÀüÁ¦Á¶°Ç
    • Æ÷ÇÔ°ú Á¦¿Ü
    • Á¦ÇÑ »çÇ×
    • ºÐ¼® ´ë»ó ±â°£

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • CEO/CXOÀÇ ÀÔÀå
  • Àü·«Àû ÀλçÀÌÆ®
  • ESG ºÐ¼®
  • ÁÖ¿ä ºÐ¼® °á°ú

Á¦3Àå ¼¼°èÀÇ ÁÖÀÔ ÆßÇÁ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ¿ªÇÐ ºÐ¼®

  • ¼¼°èÀÇ ÁÖÀÔ ÆßÇÁ ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀ» Á¿ìÇÏ´Â ½ÃÀå ¿ªÇÐ(2024-2035³â)
  • ¼ºÀå ÃËÁø¿äÀÎ
    • Åõ¾à ¾ÈÀü¼º Çâ»óÀ» ¸ñÀûÀ¸·Î ÇÑ ½º¸¶Æ® ÁÖÀÔ ½Ã½ºÅÛ ¹× ¾à¹° °ú¿À »è°¨ ½Ã½ºÅÛ(DERS) µµÀÔ Áõ°¡
    • ¸¸¼ºÁúȯÀÇ ºÎ´ãÀ̳ª ÀÚµ¿È­µÈ ÀÓ»ó ¿öÅ©ÇÃ·Î¿ì ¹× EHR°úÀÇ »óÈ£¿î¿ë¼º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±¸Çö ¹× ÅëÇÕÀÇ ºñ¿ëÀÌ ³ô°í, ·¹°Å½Ã ½Ã½ºÅÛÀÇ È£È¯¼º ¹®Á¦ ¹ß»ý
    • »çÀ̹ö º¸¾È À§Çè, ȯÀÚ µ¥ÀÌÅÍÀÇ ÇÁ¶óÀ̹ö½Ã¿¡ ´ëÇÑ ¿ì·Á, º¹ÀâÇÑ ±ÔÁ¦ ¹× ÄÄÇöóÀ̾𽺠ȯ°æ
  • ±âȸ
    • AI ±¸µ¿ °¨½Ã, ¿¹Ãø ºÐ¼®, Ŭ¶ó¿ìµå ±â¹Ý µð¹ÙÀ̽º °ü¸® Ç÷§Æû ÅëÇÕ
    • ½ÅÈï ½ÃÀå ÁøÃâ°ú ¿Ü·¡ Áø·á ¹× ÀçÅà ÁÖÀÔ ¼­ºñ½ºÀÇ ¼ºÀå

Á¦4Àå ¼¼°èÀÇ ÁÖÀÔ ÆßÇÁ ¼ÒÇÁÆ®¿þ¾î »ê¾÷ÀÇ ºÐ¼®

  • Porter's Five Forces ºÐ¼®
    • ±¸¸ÅÀÚÀÇ Çù»ó·Â
    • °ø±ÞÀÚÀÇ Çù»ó·Â
    • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's Five Forces : ¿¹Ãø ¸ðµ¨(2024-2035³â)
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸÀû
    • ±â¼úÀû
    • ȯ°æÀû
    • ¹ýÀû
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«(2025³â)
  • ½ÃÀå Á¡À¯À² ºÐ¼®(2024-2025³â)
  • ¼¼°èÀÇ °¡°Ý ºÐ¼® ¹× µ¿Çâ(2025³â)
  • ¾Ö³Î¸®½ºÆ®ÀÇ ±Ç°í ¹× °á·Ð

Á¦5Àå ¼¼°èÀÇ ÁÖÀÔ ÆßÇÁ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : À¯Çüº°(2025-2035³â)

  • ½ÃÀå °³¿ä
  • ¼¼°èÀÇ ÁÖÀÔ ÆßÇÁ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ½ÇÀû : ÀáÀç·Â ºÐ¼®(2025³â)
  • DERS(Åõ¾à °ú¿À »è°¨ ½Ã½ºÅÛ)
  • »óÈ£ ¿î¿ë¼º
  • ÀÓ»ó ¿öÅ©Ç÷οì

Á¦6Àå ¼¼°èÀÇ ÁÖÀÔ ÆßÇÁ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : ÀûÀÀÁõº°(2025-2035³â)

  • ½ÃÀå °³¿ä
  • ¼¼°èÀÇ ÁÖÀÔ ÆßÇÁ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ½ÇÀû : ÀáÀç·Â ºÐ¼®(2025³â)
  • ÀϹÝÀûÀÎ ÁÖÀÔ
  • ÅëÁõ ¹× ¸¶Ãë °ü¸®
  • Àν¶¸° ÁÖÀÔ

Á¦7Àå ¼¼°èÀÇ ÁÖÀÔ ÆßÇÁ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : Áö¿ªº°(2025-2035³â)

  • Áö¿ª ½ÃÀå ÇöȲ
  • ÁÖ¿ä ¼±Áø±¹ ¹× ½ÅÈï±¹
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • »ç¿ìµð¾Æ¶óºñ¾Æ(KSA)
    • ³²¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï Á¤º¸

  • ÁÖ¿ä ½ÃÀåÀÇ Àü·«
  • Becton, Dickinson and Company(BD)
    • ±â¾÷ °³¿ä
    • ÁÖ¿ä °£ºÎ
    • ±â¾÷ÀÇ ½º³À¼¦
    • À繫½ÇÀû(µ¥ÀÌÅÍÀÇ À̿밡´É¼º¿¡ µû¶ó ´Ù¸§)
    • Á¦Ç° ¹× ¼­ºñ½º Æ÷Æ®Æú¸®¿À
    • ÃÖ±Ù °³¹ß
    • ½ÃÀå Àü·«
    • SWOT ºÐ¼®
  • Baxter International Inc.
  • ICU Medical, Inc.
  • Fresenius Kabi AG
  • Medtronic plc
  • Smiths Medical(ICU Medical Subsidiary)
  • Terumo Corporation
  • Moog Inc.
  • Mindray Medical International Limited
  • Zyno Medical LLC
  • B. Braun Melsungen AG
  • Hospira Inc.(Pfizer)
  • Q-Core Medical Ltd.
  • Ypsomed Holding AG
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
AJY 25.09.03

The Global Infusion Pump Software Market, valued at approximately USD 1.04 billion in 2024, is poised to witness steady expansion at a CAGR of 2.21% during the forecast period from 2025 to 2035. Infusion pump software forms the backbone of modern infusion therapy, providing precision, safety, and interoperability in the administration of medications and fluids. This sophisticated software manages dosage accuracy, integrates with hospital information systems, and ensures compliance with clinical protocols, thereby enhancing patient safety and operational efficiency. The market's growth is driven by rising adoption of smart infusion systems, escalating prevalence of chronic diseases requiring long-term infusion therapy, and increasing demand for healthcare automation to minimize medication errors. In an era where data-driven healthcare is rapidly becoming the standard, infusion pump software serves as a critical enabler of real-time monitoring and clinical decision support.

The acceleration in digital transformation within healthcare has significantly amplified the demand for infusion pump software, as healthcare providers seek to optimize workflow efficiency, reduce adverse drug events, and comply with stringent regulatory standards. Demand is further propelled by technological advancements, such as the integration of drug error reduction systems (DERS) and seamless interoperability with electronic health records (EHRs). According to industry reports, medication errors contribute to thousands of preventable deaths annually, prompting healthcare facilities to invest in robust, intelligent software platforms that can preemptively identify and mitigate risks. Moreover, the growing prevalence of diabetes, cancer, and post-surgical care requirements is fueling adoption, while the development of AI-powered infusion monitoring solutions presents new opportunities for innovation. However, challenges such as high implementation costs, interoperability limitations across legacy systems, and cybersecurity concerns remain potential restraints over the forecast horizon.

From a regional perspective, North America currently dominates the infusion pump software market, supported by advanced healthcare infrastructure, strong regulatory compliance frameworks, and early adoption of medical software innovations. The United States, in particular, leads due to its high penetration of smart infusion systems and integration of EHRs across healthcare networks. Europe follows closely, driven by rising healthcare digitalization, supportive government initiatives for patient safety, and well-established clinical standards in countries such as Germany, the UK, and France. The Asia Pacific region is projected to witness the fastest growth during 2025-2035, propelled by increasing healthcare expenditure, rapid hospital modernization in emerging economies like China and India, and a surge in chronic disease management programs. Meanwhile, the Middle East & Africa and Latin America are gradually expanding their adoption of infusion pump software, spurred by ongoing healthcare reforms and investments in health IT infrastructure.

Major market players included in this report are:

  • Becton, Dickinson and Company (BD)
  • Baxter International Inc.
  • ICU Medical, Inc.
  • Fresenius Kabi AG
  • Medtronic plc
  • Smiths Medical (ICU Medical Subsidiary)
  • Terumo Corporation
  • Moog Inc.
  • Mindray Medical International Limited
  • Zyno Medical LLC
  • B. Braun Melsungen AG
  • Hospira Inc. (Pfizer)
  • Q-Core Medical Ltd.
  • Ypsomed Holding AG
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

Global Infusion Pump Software Market Report Scope:

  • Historical Data - 2023, 2024
  • Base Year for Estimation - 2024
  • Forecast period - 2025-2035
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:

By Type:

  • DERS
  • Interoperability
  • Clinical Workflow

By Indication:

  • General Infusion
  • Pain & Anesthesia Management
  • Insulin Infusion

By End User:

  • Hospitals
  • Ambulatory Care Settings

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2025 to 2035.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Infusion Pump Software Market Report Scope & Methodology

  • 1.1. Research Objective
  • 1.2. Research Methodology
    • 1.2.1. Forecast Model
    • 1.2.2. Desk Research
    • 1.2.3. Top Down and Bottom-Up Approach
  • 1.3. Research Attributes
  • 1.4. Scope of the Study
    • 1.4.1. Market Definition
    • 1.4.2. Market Segmentation
  • 1.5. Research Assumption
    • 1.5.1. Inclusion & Exclusion
    • 1.5.2. Limitations
    • 1.5.3. Years Considered for the Study

Chapter 2. Executive Summary

  • 2.1. CEO/CXO Standpoint
  • 2.2. Strategic Insights
  • 2.3. ESG Analysis
  • 2.4. Key Findings

Chapter 3. Global Infusion Pump Software Market Forces Analysis

  • 3.1. Market Forces Shaping The Global Infusion Pump Software Market (2024-2035)
  • 3.2. Drivers
    • 3.2.1. Rising adoption of smart infusion systems and drug error reduction systems (DERS) to improve medication safety
    • 3.2.2. Increasing chronic disease burden and demand for automated clinical workflows and interoperability with EHRs
  • 3.3. Restraints
    • 3.3.1. High implementation and integration costs, and legacy system compatibility issues
    • 3.3.2. Cybersecurity risks, patient data privacy concerns and complex regulatory/compliance environment
  • 3.4. Opportunities
    • 3.4.1. Integration of AI-driven monitoring, predictive analytics and cloud-based device management platforms
    • 3.4.2. Expansion into emerging markets and growth of ambulatory care and home infusion services

Chapter 4. Global Infusion Pump Software Industry Analysis

  • 4.1. Porter's 5 Forces Model
    • 4.1.1. Bargaining Power of Buyer
    • 4.1.2. Bargaining Power of Supplier
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Forecast Model (2024-2035)
  • 4.3. PESTEL Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top Investment Opportunities
  • 4.5. Top Winning Strategies (2025)
  • 4.6. Market Share Analysis (2024-2025)
  • 4.7. Global Pricing Analysis And Trends 2025
  • 4.8. Analyst Recommendation & Conclusion

Chapter 5. Global Infusion Pump Software Market Size & Forecasts by Type 2025-2035

  • 5.1. Market Overview
  • 5.2. Global Infusion Pump Software Market Performance - Potential Analysis (2025)
  • 5.3. DERS (Drug Error Reduction Systems)
    • 5.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 5.3.2. Market size analysis, by region, 2025-2035
  • 5.4. Interoperability
    • 5.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 5.4.2. Market size analysis, by region, 2025-2035
  • 5.5. Clinical Workflow
    • 5.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 5.5.2. Market size analysis, by region, 2025-2035

Chapter 6. Global Infusion Pump Software Market Size & Forecasts by Indication 2025-2035

  • 6.1. Market Overview
  • 6.2. Global Infusion Pump Software Market Performance - Potential Analysis (2025)
  • 6.3. General Infusion
    • 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 6.3.2. Market size analysis, by region, 2025-2035
  • 6.4. Pain & Anesthesia Management
    • 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 6.4.2. Market size analysis, by region, 2025-2035
  • 6.5. Insulin Infusion
    • 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
    • 6.5.2. Market size analysis, by region, 2025-2035

Chapter 7. Global Infusion Pump Software Market Size & Forecasts by Region 2025-2035

  • 7.1. Infusion Pump Software Market, Regional Market Snapshot
  • 7.2. Top Leading & Emerging Countries
  • 7.3. North America Infusion Pump Software Market
    • 7.3.1. U.S. Infusion Pump Software Market
      • 7.3.1.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.3.1.2. End User breakdown size & forecasts, 2025-2035
    • 7.3.2. Canada Infusion Pump Software Market
      • 7.3.2.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.3.2.2. End User breakdown size & forecasts, 2025-2035
  • 7.4. Europe Infusion Pump Software Market
    • 7.4.1. UK Infusion Pump Software Market
      • 7.4.1.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.4.1.2. End User breakdown size & forecasts, 2025-2035
    • 7.4.2. Germany Infusion Pump Software Market
      • 7.4.2.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.4.2.2. End User breakdown size & forecasts, 2025-2035
    • 7.4.3. France Infusion Pump Software Market
      • 7.4.3.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.4.3.2. End User breakdown size & forecasts, 2025-2035
    • 7.4.4. Spain Infusion Pump Software Market
      • 7.4.4.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.4.4.2. End User breakdown size & forecasts, 2025-2035
    • 7.4.5. Italy Infusion Pump Software Market
      • 7.4.5.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.4.5.2. End User breakdown size & forecasts, 2025-2035
    • 7.4.6. Rest of Europe Infusion Pump Software Market
      • 7.4.6.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.4.6.2. End User breakdown size & forecasts, 2025-2035
  • 7.5. Asia Pacific Infusion Pump Software Market
    • 7.5.1. China Infusion Pump Software Market
      • 7.5.1.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.5.1.2. End User breakdown size & forecasts, 2025-2035
    • 7.5.2. India Infusion Pump Software Market
      • 7.5.2.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.5.2.2. End User breakdown size & forecasts, 2025-2035
    • 7.5.3. Japan Infusion Pump Software Market
      • 7.5.3.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.5.3.2. End User breakdown size & forecasts, 2025-2035
    • 7.5.4. Australia Infusion Pump Software Market
      • 7.5.4.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.5.4.2. End User breakdown size & forecasts, 2025-2035
    • 7.5.5. South Korea Infusion Pump Software Market
      • 7.5.5.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.5.5.2. End User breakdown size & forecasts, 2025-2035
    • 7.5.6. Rest of APAC Infusion Pump Software Market
      • 7.5.6.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.5.6.2. End User breakdown size & forecasts, 2025-2035
  • 7.6. Latin America Infusion Pump Software Market
    • 7.6.1. Brazil Infusion Pump Software Market
      • 7.6.1.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.6.1.2. End User breakdown size & forecasts, 2025-2035
    • 7.6.2. Mexico Infusion Pump Software Market
      • 7.6.2.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.6.2.2. End User breakdown size & forecasts, 2025-2035
  • 7.7. Middle East and Africa Infusion Pump Software Market
    • 7.7.1. UAE Infusion Pump Software Market
      • 7.7.1.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.7.1.2. End User breakdown size & forecasts, 2025-2035
    • 7.7.2. Saudi Arabia (KSA) Infusion Pump Software Market
      • 7.7.2.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.7.2.2. End User breakdown size & forecasts, 2025-2035
    • 7.7.3. South Africa Infusion Pump Software Market
      • 7.7.3.1. Type & Indication breakdown size & forecasts, 2025-2035
      • 7.7.3.2. End User breakdown size & forecasts, 2025-2035

Chapter 8. Competitive Intelligence

  • 8.1. Top Market Strategies
  • 8.2. Becton, Dickinson and Company (BD)
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Financial Performance (Subject to Data Availability)
    • 8.2.5. Product/Services Port
    • 8.2.6. Recent Development
    • 8.2.7. Market Strategies
    • 8.2.8. SWOT Analysis
  • 8.3. Baxter International Inc.
  • 8.4. ICU Medical, Inc.
  • 8.5. Fresenius Kabi AG
  • 8.6. Medtronic plc
  • 8.7. Smiths Medical (ICU Medical Subsidiary)
  • 8.8. Terumo Corporation
  • 8.9. Moog Inc.
  • 8.10. Mindray Medical International Limited
  • 8.11. Zyno Medical LLC
  • 8.12. B. Braun Melsungen AG
  • 8.13. Hospira Inc. (Pfizer)
  • 8.14. Q-Core Medical Ltd.
  • 8.15. Ypsomed Holding AG
  • 8.16. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦